These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 36681177)
1. Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy. Hodl I; Sallegger C; Forstner P; Sareban N; Moritz M; Dreo B; Schulz E; Lackner A; Kleinhappl B; Hatzl S; Moazedi-Fürst F; Seifert-Held T; Heschl B; Khalil M; Enzinger C; Greinix H; Stradner MH; Steinmetz I; Schlenke P; Fessler J Microbes Infect; 2023 May; 25(4):105103. PubMed ID: 36681177 [TBL] [Abstract][Full Text] [Related]
2. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T Front Immunol; 2022; 13():834981. PubMed ID: 35154159 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy. Bazzi SA; Maguire C; Holay N; Geltman J; Hurley K; DiPasquale C; Abigania M; Olson E; Ehrlich LIR; Triplett TA; Melamed E Mult Scler Relat Disord; 2022 Dec; 68():104195. PubMed ID: 36223705 [TBL] [Abstract][Full Text] [Related]
5. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554 [TBL] [Abstract][Full Text] [Related]
6. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Riise J; Meyer S; Blaas I; Chopra A; Tran TT; Delic-Sarac M; Hestdalen ML; Brodin E; Rustad EH; Dai KZ; Vaage JT; Nissen-Meyer LSH; Sund F; Wader KF; Bjornevik AT; Meyer PA; Nygaard GO; König M; Smeland S; Lund-Johansen F; Olweus J; Kolstad A Br J Haematol; 2022 Jun; 197(6):697-708. PubMed ID: 35254660 [TBL] [Abstract][Full Text] [Related]
7. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197 [TBL] [Abstract][Full Text] [Related]
8. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360 [TBL] [Abstract][Full Text] [Related]
9. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A; Front Immunol; 2022; 13():868915. PubMed ID: 35432335 [TBL] [Abstract][Full Text] [Related]
10. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab. Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S Front Immunol; 2023; 14():1254128. PubMed ID: 37841269 [TBL] [Abstract][Full Text] [Related]
13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
14. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. Alfonso-Dunn R; Lin J; Kirschner V; Lei J; Feuer G; Malin M; Liu J; Roche M; Sadiq SA Front Immunol; 2022; 13():926318. PubMed ID: 35990701 [TBL] [Abstract][Full Text] [Related]
15. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination. Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B Front Immunol; 2022; 13():942192. PubMed ID: 36275696 [TBL] [Abstract][Full Text] [Related]